Genesis Bioventures Announces Name Change to Abviva, Inc.LOS ANGELES -- Genesis Bioventures, Inc. (GBI GBI Georgia Bureau of Investigation GBI Green Building Initiative GBI Ground Based Interceptor GBI Grand Bahama Island GBI Green Bank Interferometer GBI Generic Bus Interface GBI Gain By Inventory GBI Garrett Bureau of Investigation ) (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :GBIW) today announced that it has completed its planned name change of the corporation to Abviva, Inc. Genesis Bioventures changed its corporate name to Abviva, Inc. to emphasize its mission to commercialize the Mammastatin Serum Assay ("MSA (Metropolitan Service Area) An urban area with at least 50,000 people plus surrounding counties. There are 306 MSAs and 428 RSAs (rural service areas) in the U.S. MSAs and RSAs are used to allocate cellular licenses. ") and to pursue development of the mammastatin protein as a possible first line therapy against breast cancer. The name change was approved by the shareholders at the 2007 Annual Shareholders Meeting held on September 14, 2007 as part of the Company's completion of its reorganization and restructuring plan. "We determined that the Company requires a name that represents its mission and commitment to the mammastatin technology for breast cancer diagnostics and therapeutics," said Douglas C. Lane, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . Abviva is a name inspired from a Latin phrase meaning 'From Life'. Mammastatin is normally present in healthy women and therefore comes from life. This technology is used to develop and offer innovative diagnostic and therapeutic products 'For Life', beginning with the Mammastatin Serum Assay." The Company will continue to be traded under the ticker symbol Ticker Symbol An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors GBIW on the NASD NASD See: National Association of Securities Dealers NASD See National Association of Securities Dealers (NASD). OTCBB market. The Company has applied for a new ticker symbol representative of its new name. Abviva will announce the new ticker symbol when it receives notice from the regulatory agencies. The Company's new website is under construction and will be available at www.abviva.com. About Abviva (formerly known as Genesis Bioventures, Inc.) Abviva, Inc. is a biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. company focused on the commercialization of its owned and licensed assets for breast cancer diagnostics and for breast cancer therapeutic development. Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion